Dietmar Berger compensation by year
GILEAD SCIENCES Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $969,231 |
| Bonus | $3,000,000 |
| Stock awards | $6,999,758 |
| Option awards | $1,000,043 |
| Non-equity incentive | $1,603,594 |
| Pension and deferred compensation | $0 |
| All other | $350,252 |
| Total | $13,922,878 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: GILEAD SCIENCES, INC. DEF 14A filed March 20, 2026, accession 0001308179-26-000106, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 48,975 | $6,011,192 | — |
| RSU | 8,530 | $1,046,972 | — |
| PSU | 5,725 | $702,687 | — |
| Option | 37,710 | — | $117.21 |
Per the Outstanding Equity Awards at Fiscal Year-End table in GILEAD SCIENCES, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
6 Form 4 lines since the FY2025 proxy (filed March 20, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-10 | Exercise or conversion | — | 533 | — | 19,785 |
| 2026-09-10 | Tax withholding | — | 263 | $144.81 | 19,522 |
| 2026-09-10 | Exercise or conversion derivative | — | 533 | — | 46,395 |
| 2026-06-10 | Exercise or conversion derivative | — | 533 | — | 46,928 |
| 2026-06-10 | Exercise or conversion | — | 533 | — | 19,515 |
| 2026-06-10 | Tax withholding | — | 263 | $121.48 | 19,252 |
The 6 most recent of 6 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
GILEAD SCIENCES’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Daniel O'Day | Chairman and Chief Executive Officer | $28,437,198 |
| Dietmar Berger · this page | Chief Medical Officer | $13,922,878 |
| Johanna Mercier | Chief Commercial and Corporate Affairs Officer | $9,300,643 |
| Andrew Dickinson | Chief Financial Officer | $8,765,616 |
| Deborah Telman | Former Executive Vice President, Corporate Affairs and General Counsel | $5,004,669 |
The full GILEAD SCIENCES compensation record
free company briefThis page is one person within GILEAD SCIENCES's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order GILEAD SCIENCES's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are GILEAD SCIENCES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat